The Future of the Genetic Testing Market: 23andMe's Share Price Plunge Highlights Challenges and Value-Added Offerings Other Than B2B2C Models and SNPs

This podcast examines the current status and challenges of the genetic testing market, especially the limitations of its business model and new strategies for the future against the backdrop of 23andMe's plummeting stock price. While introducing the trends of major domestic and overseas players, the article proposes solutions to the challenges of monetization, such as the introduction of a subscription model and a shift to a BtoB business. It also points out the importance of structural mutation analysis and multi-omics analysis as added value other than SNP analysis, and discusses issues in collaboration with pharmaceutical companies and the necessary sample size.